CLINICAL RESEARCH: METABOLIC SYNDROME AND RISK
Insulin Resistance, the Metabolic Syndrome, and Risk of Incident Cardiovascular DiseaseA Population-Based Study
Jørgen Jeppesen, MD, DMSc*,*,
Tine W. Hansen, MD, PhD , ,
Susanne Rasmussen, MD, PhD,
Hans Ibsen, MD, DMSc*,
Christian Torp-Pedersen, MD, DMSc and
Sten Madsbad, MD, DMSc
* Department of Medicine, Glostrup University Hospital, Glostrup, Denmark
Research Center for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark
Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark
Department of Endocrinology and Internal Medicine, Hvidovre University Hospital, Hvidovre, Denmark.
Manuscript received August 18, 2006;
revised manuscript received January 19, 2007,
accepted January 22, 2007.
* Reprint requests and correspondence: Dr. Jørgen Jeppesen, Department of Medicine, Glostrup University Hospital, Ndr. Ringvej, DK-2600 Glostrup, Denmark. (Email: jj{at}heart.dk).
Objectives: The goal was to clarify if insulin resistance (IR) would predict cardiovascular disease (CVD) independent of the metabolic syndrome (MetSyn).
Background: Although the cause of MetSyn is not well defined, IR has been proposed to be an important cause. Only a small number of population-based studies have sought to clarify if IR predicts CVD independent of MetSyn.
Methods: This was a prospective Danish population-based study of 2,493 men and women, age 41 to 72 years, without major CVD at baseline. We defined MetSyn according to both the International Diabetes Foundation (IDF) and the National Cholesterol Education Program (NCEP) criteria, and we quantified IR by the homeostasis model assessment (HOMA-IR). Prevalence of MetSyn was 21% according to IDF criteria and 16% according to NCEP criteria. Accordingly, we defined IDF-HOMA-IR as belonging to the highest 21% of the HOMA-IR distribution, and NCEP-HOMA-IR as belonging to the highest 16% of the HOMA-IR distribution.
Results: Over a median follow-up of 9.4 years, the incidence of CV end points (CV death, nonfatal ischemic heart disease, and nonfatal stroke) amounted to 233 cases. In proportional hazard models, adjusting for age, gender, smoking, and low-density lipoprotein cholesterol, and with IDF-HOMA-IR and IDF-MetSyn included in the same model, the relative risk of an end point was 1.67 (95% confidence interval [CI] 1.22 to 2.29) for IDF-HOMA-IR and 1.16 (95% CI 0.84 to 1.60) for IDF-MetSyn. The corresponding figures for NCEP-HOMA-IR and NCEP-MetSyn included in the same model were 1.49 (95% CI 1.07 to 2.07) and 1.56 (95% CI 1.12 to 2.17).
Conclusions: In this Danish study, both HOMA-IR and NCEP-MetSyn were independent predictors of incident CVD.
|
Abbreviations and Acronyms
| | BMI = body mass index | | CI = confidence interval | | CVD = cardiovascular disease | | HDL-C = high-density lipoprotein cholesterol | | HOMA = homeostasis model assessment | | HR = hazard ratio | | IDF = International Diabetes Foundation | | IR = insulin resistance | | LDL-C = low-density lipoprotein cholesterol | | MetSyn = metabolic syndrome | | NCEP = National Cholesterol Education Program |
|
This article has been cited by other articles:
|
|
|
|
 
Bin Hu, Yujie Zhou, Yuyang Liu, Dongmei Shi, Yingxin Zhao, Dean Jia, Shiwei Yang, Zhe Fang, and Bin Nie
Impact of Metabolic Syndrome on Clinical Outcomes After Drug-Eluting Stent Implantation in Patients With Coronary Artery Disease
Angiology,
August 1, 2011;
62(6):
440 - 446.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. J. Robins, A. Lyass, J. P. Zachariah, J. M. Massaro, and R. S. Vasan
Insulin Resistance and the Relationship of a Dyslipidemia to Coronary Heart Disease: The Framingham Heart Study
Arterioscler Thromb Vasc Biol,
May 1, 2011;
31(5):
1208 - 1214.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. E. Schauer, J. K. Snell-Bergeon, B. C. Bergman, D. M. Maahs, A. Kretowski, R. H. Eckel, and M. Rewers
Insulin Resistance, Defective Insulin-Mediated Fatty Acid Suppression, and Coronary Artery Calcification in Subjects With and Without Type 1 Diabetes: The CACTI Study
Diabetes,
January 1, 2011;
60(1):
306 - 314.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Hankey and T. Z. Feng
Insulin Resistance a Possible Causal and Treatable Risk Factor for Ischemic Stroke
Arch Neurol,
October 1, 2010;
67(10):
1177 - 1178.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Rundek, H. Gardener, Q. Xu, R. B. Goldberg, C. B. Wright, B. Boden-Albala, N. Disla, M. C. Paik, M. S. V. Elkind, and R. L. Sacco
Insulin Resistance and Risk of Ischemic Stroke Among Nondiabetic Individuals From the Northern Manhattan Study
Arch Neurol,
October 1, 2010;
67(10):
1195 - 1200.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mottillo, K. B. Filion, J. Genest, L. Joseph, L. Pilote, P. Poirier, S. Rinfret, E. L. Schiffrin, and M. J. Eisenberg
The Metabolic Syndrome and Cardiovascular Risk: A Systematic Review and Meta-Analysis
J. Am. Coll. Cardiol.,
September 28, 2010;
56(14):
1113 - 1132.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. He, E. T. S. Li, S. Harris, M. W. Huff, C. Y. Yau, and G. H. Anderson
Canadian global village reality: Anthropometric surrogate cutoffs and metabolic abnormalities among Canadians of East Asian, South Asian, and European descent
Can Fam Physician,
May 1, 2010;
56(5):
e174 - e182.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Tzoulaki, G. Liberopoulos, and J. P. A. Ioannidis
Assessment of Claims of Improved Prediction Beyond the Framingham Risk Score
JAMA,
December 2, 2009;
302(21):
2345 - 2352.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Ruggenenti, D. Cattaneo, G. Loriga, F. Ledda, N. Motterlini, G. Gherardi, S. Orisio, and G. Remuzzi
Ameliorating Hypertension and Insulin Resistance in Subjects at Increased Cardiovascular Risk: Effects of Acetyl-L-Carnitine Therapy
Hypertension,
September 1, 2009;
54(3):
567 - 574.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E. Noel, P. K. Newby, J. M. Ordovas, and K. L. Tucker
A Traditional Rice and Beans Pattern Is Associated with Metabolic Syndrome in Puerto Rican Older Adults
J. Nutr.,
July 1, 2009;
139(7):
1360 - 1367.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W. Knuiman, J. Hung, M. L. Divitini, T. M. Davis, and J. P. Beilby
Utility of the metabolic syndrome and its components in the prediction of incident cardiovascular disease: a prospective cohort study
European Journal of Cardiovascular Prevention & Rehabilitation,
April 1, 2009;
16(2):
235 - 241.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Qiao, T. Laatikainen, B. Zethelius, B. Stegmayr, M. Eliasson, P. Jousilahti, and J. Tuomilehto
Comparison of Definitions of Metabolic Syndrome in Relation to the Risk of Developing Stroke and Coronary Heart Disease in Finnish and Swedish Cohorts
Stroke,
February 1, 2009;
40(2):
337 - 343.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-A. Cornier, D. Dabelea, T. L. Hernandez, R. C. Lindstrom, A. J. Steig, N. R. Stob, R. E. Van Pelt, H. Wang, and R. H. Eckel
The Metabolic Syndrome
Endocr. Rev.,
December 1, 2008;
29(7):
777 - 822.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Jeppesen, T. W. Hansen, M. H. Olsen, S. Rasmussen, H. lbsen, C. Torp-Pedersen, P. R. Hildebrandt, and S. Madsbad
C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study
European Journal of Cardiovascular Prevention & Rehabilitation,
October 1, 2008;
15(5):
594 - 598.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Chinali, G. de Simone, M. J. Roman, L. G. Best, E. T. Lee, M. Russell, B. V. Howard, and R. B. Devereux
Cardiac Markers of Pre-Clinical Disease in Adolescents With the Metabolic Syndrome: The Strong Heart Study
J. Am. Coll. Cardiol.,
September 9, 2008;
52(11):
932 - 938.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Blaha, S. Bansal, R. Rouf, S. H. Golden, R. S. Blumenthal, and A. P. DeFilippis
A Practical 'ABCDE' Approach to the Metabolic Syndrome
Mayo Clin. Proc.,
August 1, 2008;
83(8):
932 - 943.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
